How many insider trades does FilingIQ track for MYGN?

FilingIQ tracks 908 Form 4 insider transactions for MYGN (MYRIAD GENETICS INC), covering filings from Aug 13, 2015 onwards. 40 of those were filed in the last 90 days.

Are MYGN insiders net buyers or net sellers?

Across the full Form 4 history for MYGN, 14 transactions (2%) were open-market purchases and 137 (15%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does MYGN insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is MYGN in?

MYRIAD GENETICS INC (MYGN) is classified in the Healthcare sector, specifically Diagnostics & Research, with a current market capitalisation of $429.25M.

MYGN insider trading

NasdaqGS Healthcare

MYRIAD GENETICS INC — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

908

Last 90 days

Buys / sells

2% / 15%

Market cap

$429.25M

About MYRIAD GENETICS INC

Myriad Genetics, Inc., a molecular diagnostic testing and precision medicine company, develops and provides molecular tests. The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test to help determine the therapy for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. In addition, the company offers Prolaris Prostate Cancer Prognostic test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor Molecular Profile test, a genomic profiling test; Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus; Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek Early Gender DNA test, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit/hyperactivity disorder, and other mental health conditions. It has a license collaboration with Illumina, Inc.; Memorial Sloan Kettering Cancer Center; the University of Texas MD Anderson Cancer Center; the University of Rochester Medical Center; and Flatiron Health, Inc. The company has a strategic alliance with SOPHiA GENETICS SA for the development of liquid biopsy companion diagnostic (CDx) test. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.

Company website: www.myriad.com

MYGN insider activity at a glance

FilingIQ has scored 908 insider transactions for MYGN since Aug 13, 2015. The most recent filing in our index is dated May 14, 2026.

Across the full history, 14 open-market purchases and 137 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on MYGN insider trades is 57.3/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live MYGN trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

Frequently asked

How many insider trades does FilingIQ track for MYGN?: FilingIQ tracks 908 Form 4 insider transactions for MYGN (MYRIAD GENETICS INC), covering filings from Aug 13, 2015 onwards. 40 of those were filed in the last 90 days.
Are MYGN insiders net buyers or net sellers?: Across the full Form 4 history for MYGN, 14 transactions (2%) were open-market purchases and 137 (15%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does MYGN insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is MYGN in?: MYRIAD GENETICS INC (MYGN) is classified in the Healthcare sector, specifically Diagnostics & Research, with a current market capitalisation of $429.25M.

Methodology & sources

Every MYGN insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.